FJY Stock Chart & Stats
€0.02
<€0.01(18.75%)
At close: 4:00 PM EST
€0.02
<€0.01(18.75%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.02
Previous CloseN/A
Volume10.00K
Average Volume (3M)10.00K
Market Cap
€3.82M
Enterprise Value€5.85M
Total Cash (Recent Filing)€1.71M
Total Debt (Recent Filing)€2.52M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding612,154,100
10 Day Avg. Volume10,000
30 Day Avg. Volume10,000
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.46
Price to Sales (P/S)1.09
P/FCF Ratio4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€8.87M
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe strong 2026 revenue rebound indicates that demand can recover after a period of contraction. If maintained, higher sales could improve operating leverage, support continued commercialization, and provide a more durable foundation for reducing losses over the next several quarters.
Improved Cash GenerationPositive operating and free cash flow in the latest year is an important improvement for a company that has experienced earlier cash burn. Sustained cash generation would reduce reliance on external funding and give management greater flexibility to support ongoing operations.
Narrower Net LossA materially smaller net loss shows progress toward financial breakeven, even though profitability has not yet been achieved. Continued improvement would strengthen the earnings trajectory, reduce the burden of recurring losses, and make future growth more financially sustainable.
Bears Say
Persistent UnprofitabilityPersistent losses indicate that the business has not yet demonstrated a sustainable profit model. Continued negative EBIT and EBITDA can consume financial resources, limit internally funded investment, and leave results vulnerable if the recent revenue recovery does not continue.
Weakened Balance SheetHigher leverage alongside a smaller equity cushion increases balance-sheet risk for a biotechnology company with recurring losses. This weaker capital structure reduces financial flexibility and may constrain the ability to absorb setbacks or fund operations without additional financing.
Volatile Financial PerformanceLarge swings in revenue and free cash flow make the recent improvement harder to treat as a stable trend. If sales normalize or costs rise, cash burn could return, increasing uncertainty around liquidity and making consistent progress toward profitability more difficult.
Acrux News
FJY FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest stock price was <€0.01 and its highest was €0.02 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is €3.82M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Mar 02, 2027 which is in 130 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Aug 21, 2026. The company reported -€0.001 earnings per share for the quarter.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited does not currently pay dividends.
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 612,154,100 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went down -21.429%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in DE:FJY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
DE:FJY Sentiment 50%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth €93.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-45.29%
Trailing 12-Months
Asset Growth
-12.39%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Acrux Limited
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets. The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels. Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.
Technical Analysis
Clinuvel Pharmaceuticals
―
Starpharma Holdings Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―